Visiting Dana-Farber? See our prescreening and mask requirements.
Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a live medical interpreter for a discussion about your care.
— Clifton Mo, MD and Utkarsh Acharya, DO, FACP
While arguably overused, the term "unprecedented" thematically encapsulates the maelstrom that was 2020. Few other adjectives can as effectively capture the struggles we have collectively experienced and witnessed since the beginning of this
(hopefully) once-in-a-lifetime pandemic. However, despite the pejorative connotations associated with its use, unprecedented can also serve as an inspirational term to define the depth of ingenuity, heroism, sacrifice, compassion, and empathy
showcased by countless colleagues, patients, and caregivers over the course of the past year.
Scientifically, the rapid bench-to-chairside development of highly efficacious mRNA vaccines against SARS-CoV-2 is nothing short of an unprecedented accomplishment, and in this context, we are proud to acknowledge Lindsey Baden, MD,
Dana-Farber infectious disease faculty and COVE trial co-principal investigator, on a job well done.
Institutionally, Dana-Farber has risen to the enormous challenge of continuing to provide world-class clinical care during a time of crisis, and within the Hematologic Malignancies (HM) Division, we must acknowledge the leadership of Rob Soiffer, MD,
Martha Wadleigh, MD, and Julie Porter, who have collectively allowed us to maintain an unwavering standard of excellence for our patients.
Recognizing that cancer does not stop for COVID-19, neither have our HM faculty, as exhibited through the numerous advances in clinical and translational research that were made within our division despite the pandemic. At the 62nd ASH Annual
Meeting held virtually for the first (and hopefully last) time in December 2020, Dana-Farber HM investigators presented more than 40 oral abstracts — reporting on key clinical trials, correlative studies, and pre-clinical efforts across the different
While we unfortunately cannot include every notable study in this issue, we are proud to highlight four abstracts that we consider to be particularly noteworthy in terms of either immediate or eventual potential for practice-changing impact:
As can be seen, the extent of scientific and clinical advances made by our colleagues over the course of the most difficult of years has been unprecedented in the best sense of the word. Accordingly, we hope you find this newsletter as interesting
and exciting as we do — and we wish everyone a safer, happier, and more prosperous 2021.
— Cliff and Utty
Find more information on our program's participation at ASH 2020.
Clifton Mo, MD, Jerome Lipper Multiple Myeloma Center
Utkarsh Acharya, DO, FACP, Division of Stem Cell Transplantation and Cellular Therapies